
October
7, 2005 |
Herscots'
generosity opens new doors in understanding, treating TSC
It affects more patients than cystic fibrosis and muscular dystrophy;
can cause a broad spectrum of conditions ranging from epilepsy to benign
tumors; and afflicts both children and adults alike. Yet tuberous sclerosis
complex — known as TSC — has, until recently, largely been
a disease of mystery. While it may be genetically inherited, TSC also
can occur randomly and sporadically in families, making it all the more
elusive to trace and understand. As difficult to identify as it is to
treat, the disease often forces patients to travel from hospital to hospital
in search of a firm diagnosis and an established treatment plan.
Longtime MGH supporters Carol and James Herscot believe all of that will
change, thanks to the opening of the Carol and James Herscot Center for
Tuberous Sclerosis Complex, which was formally dedicated at the hospital
Sept. 26. The center was established by a generous gift from the Herscots
and is the first clinical facility of its kind to address the dual diagnostic
and treatment challenges posed by TSC for both children and adults.
The Herscots know full well the impact wrought by TSC. Nearly 40 years
ago, their son, Brad, began to suffer from seizures and other symptoms
that no specialist could seem to pinpoint — symptoms that later
proved to be driven by TSC. The Herscots then decided to devote their
lives to ensuring that other TSC patients and parents would not have to
endure what they had experienced. Though their own son is thriving and
living semi-independently today, the couple has remained dedicated allies
and advocates in educating physicians, caregivers and families nationwide
about the disease.
The Herscot Center will operate under the direction of Elizabeth Thiele,
MD, PhD (far left, pictured with the Herscots), a pediatric neurologist
at MassGeneral Hospital for Children and one of the world's leading TSC
experts. Thanks to the Herscots' commitment, the center bearing their
name now will provide an unparalleled caliber of clinical, research and
outreach initiatives for patients and families living with this previously
enigmatic disease.
|